Topiramate

Drug Profile

Topiramate

Alternative Names: Epitomax; KW-6485; KW-6485P; MCN 4853; RWJ 17021; Topamax; Topamax Migraine; Topimax; Topina; Topina fine granules

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Inc; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Pharmaceutical Research & Development; Johnson & Johnson Pharmaceutical Research & Development LLC; Kyowa Hakko Kirin; Ortho-McNeil; Xian-Janssen
  • Class Antiepileptic drugs; Antimigraines; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; GABA-A receptor antagonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy; Lennox-Gastaut syndrome; Migraine
  • Phase III Obesity
  • No development reported Post-traumatic stress disorders
  • Discontinued Bipolar disorders; Diabetic neuropathies

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Post-traumatic-stress-disorder in USA (PO)
  • 15 Mar 2016 Biomarkers information updated
  • 16 Feb 2016 Phase-III clinical trials in Obesity (In adolescents, In children) in France (PO) (EudraCT2011-006193-36)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top